TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05683847

Intervention type: OTHER
Intervention: User controlled epilepsy follow-up by means of patient reported outcome measures (PROM)
Description: Whenever they want to, but minimum every six months, users respond to standardized follow-up questions developed by the experts of EpilepsiNett. This ensures that a broader range of topics are covered, not just those related to seizures and adverse events. The incoming responses are handled by a trained epilepsy nurse, who contact the patient when needed, consulting the responsible medical doctor when needed. If current issues cannot be solved by telephonic contact with the epilepsy nurse and/or responsible medical doctor, the patient is offered an appointment at the outpatient clinic.
Study: NCT02969798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 10mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 10mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: 10mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: 5mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: 5mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saxagliptin
Description: 5mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: the dose will increase from 15 mg/day to 30 mg/day at month two

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: the dose will increase from 15 mg/day to 30 mg/day at month two

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: the dose will increase from 15 mg/day to 30 mg/day at month two

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: starting at 1000 mg/day and increased to 2000 mg/day at month 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: starting at 1000 mg/day and increased to 2000 mg/day at month 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: starting at 1000 mg/day and increased to 2000 mg/day at month 2.
Study: NCT02160080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
Description: Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
Study: NCT02715739

Intervention type: OTHER
Intervention: No intervention
Study: NCT00003468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Children with a low grade astrocytoma that have not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT00655265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride film-coated tablets
Description: tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets
Study: NCT04694222

Intervention type: DEVICE
Group type: OTHER
Intervention: Nd:YAG laser
Description: For LANAP, the fiber optic tip of the Nd:YAG laser (1064 nm) (Fotona Fidelis AT, USA) was used. For LLLT R24 biostimulation handpiece tip (950-μm) Nd:YAG laser (1064 nm) was used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nd:YAG laser
Description: For LANAP, the fiber optic tip of the Nd:YAG laser (1064 nm) (Fotona Fidelis AT, USA) was used. For LLLT R24 biostimulation handpiece tip (950-μm) Nd:YAG laser (1064 nm) was used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nd:YAG laser
Description: For LANAP, the fiber optic tip of the Nd:YAG laser (1064 nm) (Fotona Fidelis AT, USA) was used. For LLLT R24 biostimulation handpiece tip (950-μm) Nd:YAG laser (1064 nm) was used.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nd:YAG laser
Description: For LANAP, the fiber optic tip of the Nd:YAG laser (1064 nm) (Fotona Fidelis AT, USA) was used. For LLLT R24 biostimulation handpiece tip (950-μm) Nd:YAG laser (1064 nm) was used.
Study: NCT00739401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suprarenal Proximal Cuff Extension
Description: Powerlink 25 and 28mm Suprarenal Proximal Extensions augmenting the 25 and 28mm Powerlink bifurcated stent graft
Study: NCT04578600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: Given PO
Study: NCT03863184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib, oral, 100 mg BID, continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide, 15 mg for cycle 1, then escalated as tolerated to 20 mg, QD, Days 1-21 out of 28 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab, IV, weekly during Cycle 1, and every other cycle starting with Cycle 4
Study: NCT02737007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-GSK3191607
Description: \[14C\]-GSK3191607 is a solution to be administered intravenously as a single dose infusion over 15 minutes. It is a radio-labeled product; 100 mcg of \[14C\]-GSK3191607 contains approximately 7.4 kilobecquerel (kBq) of \[14C\] radioactivity.
Study: NCT01892670

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donation of 1 whole blood unit
Description: Donation of 450-500 mL of whole blood according to local blood bank procedures and national guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donation of 1 whole blood unit
Description: Donation of 450-500 mL of whole blood according to local blood bank procedures and national guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donation of 1 whole blood unit
Description: Donation of 450-500 mL of whole blood according to local blood bank procedures and national guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donation of 1 whole blood unit
Description: Donation of 450-500 mL of whole blood according to local blood bank procedures and national guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donation of 1 whole blood unit
Description: Donation of 450-500 mL of whole blood according to local blood bank procedures and national guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Donation of 1 whole blood unit
Description: Donation of 450-500 mL of whole blood according to local blood bank procedures and national guidelines.
Study: NCT02527681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftobiprole medocaril
Description: Ceftobiprole medocaril was administered as a single intravenous infusion, with a bodyweight-adjusted volume, at a constant rate over 4 hours. The ceftobiprole dose was 7.5 mg/kg, which corresponds to 10.0 mg ceftobiprole medocaril.
Study: NCT02006316

Intervention type: PROCEDURE
Intervention: Microsurgical subinguinal varicocelectomy
Study: NCT01059097

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticoduodenectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pancreaticoduodenectomy
Study: NCT01773317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perturbation
Description: All subjects complete study protocol. Subjects randomized to the perturbation group will complete the additional perturbation exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Subjects will complete the study protocol (including nordic hamstrings, standing squats, drop jumps, triple single leg hopping, and tuck jumps)
Study: NCT04396535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp Alfa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV
Study: NCT04532671

Intervention type: OTHER
Group type: OTHER
Intervention: Poly ether ether ketone (PEEK)
Description: PEEK has been used in dentistry so far in certain fields as for, removable and fixed dental prostheses, implants, and implant abutments as well as orthodontic devices, whereas in literature, it is mostly mentioned in relation to prosthetics. PEEK was predominantly processed out of CAD/CAM-supported milled out of prefabricated blanks. Producing dental restorations via Additive manufacturing is still hardly widespread

Intervention type: OTHER
Group type: OTHER
Intervention: CADCAM Poly ether ether ketone (PEEK)
Description: Increased demand for long-lasting restoration's properties have led to many improvements in the production techniques of posterior restorations such as CAD/CAM systems. This technique simplifies the production of indirect restorations and make it possible to use advanced materials as PEEK

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: indirect resin composite
Description: CADCAM resin composite blocks using milling process
Study: NCT00660725

Intervention type: DRUG
Group type: OTHER
Intervention: Vandetanib
Description: Vandetanib is a pill that will be self-administered orally on Days 1-14 of each 14-day cycle. The dose of vandetanib each subject will receive will be determined by a dose escalation schedule (either 200 mg or 300 mg per day), which will be followed to determine the MTD of the study drug combination (vandetanib + GemOx). In the absence of disease progression, unacceptable toxicities, or other complications, the vandetanib and GemOx combination may continue per protocol for a maximum of 6 cycles, or 12 weeks. In subjects who show response or stable disease, vandetanib may be continued as a single agent beyond the 6 cycle maximum, at the investigator's discretion.

Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: 30-minute IV infusion of 1000 mg/m\^2 gemcitabine on Day 1 of each 14-day cycle.

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Immediately following gemcitabine IV: 2-hour IV infusion of 85 mg/m\^2 oxaliplatin on Day 1 of each 14-day cycle.
Study: NCT03155165

Intervention type: DEVICE
Intervention: Retroview™ colonoscope
Description: The colonoscopy will be performed twice, with 2 different scopes, in tandem, by 2 endoscopists trained on retroflex withdrawal. First a conventional HD colonoscope with I-Scan will be used following the standard withdrawal technique and then the second endoscopist blinded to the first colonoscopy results, will perform the second colonoscopy using the Retroview™ scope with a combining withdrawal (retroflexed + standard withdrawal). The endoscopist that will perform each colonoscopy will be chosen randomly. After the examination, the endoscopist will fill a questionnaire detailing each polyp / adenoma found including the size and location.

Intervention type: DEVICE
Intervention: Retroview™ colonoscope
Description: The colonoscopy will be performed twice, with 2 different scopes, in tandem, by 2 endoscopists trained on retroflex withdrawal. First a conventional HD colonoscope with I-Scan will be used following the standard withdrawal technique and then the second endoscopist blinded to the first colonoscopy results, will perform the second colonoscopy using the Retroview™ scope with a combining withdrawal (retroflexed + standard withdrawal). The endoscopist that will perform each colonoscopy will be chosen randomly. After the examination, the endoscopist will fill a questionnaire detailing each polyp / adenoma found including the size and location.
Study: NCT03630835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 99mTc-Annexin-V-128 uptake on scintigraphy
Description: An intravenous catheter will be placed in the forearm and a dose of 370 Mega-Becquerels of 99mTc-Annexin-V-128 (1-2 ml) over 10 seconds will be injected through the catheter. The patient will wait for 90 minutes in semi-supine position for the clearance of the radiotracer from blood. At 90 minutes p.i., the patient will be placed in a supine position on the bed of a SPECT-CT gamma-camera. A SPECT acquisition including the heart and the brain will be performed over 20 minutes. At the end of the SPECT acquisition, the bed will move to the CT of the imaging system. A CT angiography will be acquired during the intravenous injection of 30-40 ml of iodinated CT contrast agent from the heart to the brain to localize the signal on the SPECT images. The iodinated contrast agent that is currently available at Bichat Hospital for CTA is Iomeron 400 provided by Bracco Imaging.~The total duration of the imaging study will be 2 hours.
Study: NCT00551759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Patients underwent surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Patients underwent radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33.
Study: NCT00409071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocculine®
Description: 12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
Study: NCT02587741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: start with metformin，from 500mg bid,if metformin reach the biggest dosage，added gliclazide modified release tablets，afterthat，add acarbose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lantus
Description: started with insulin glargine 0.2 u/kg subcutaneous injection ，add dosage if glucose dose not reach the target.after that,you can add oral drugs（like oral drug group）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novomix30
Description: started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs
Study: NCT02119871

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral Open Pleurae
Description: Both pleurae are opened Right pulmonary vein drainage

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right Pleura Open
Description: Right pleura open Left ventricular apical drainage
Study: NCT00664547

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet Weight Loss

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Weight Loss

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Without Weight Loss
Study: NCT02763423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord mesenchymal stem cell
Description: allogeneic umbilical cord mesenchymal stem cell transplantation by intravenous injection
Study: NCT03028298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose sildenafil citrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose sildenafil citrate
Study: NCT00866424

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen, Mock hyperbaric chamber
Description: Hyperbaric oxygen treatment for 10 days in treatment groups and mock hyperbaric chamber treatment for 10 days in control groups.~Hyperbaric oxygen treatment: While in the hyperbaric chamber the subjects breathe 100% oxygen saturation with mask at 2.0bars.~Mock hyperbaric chamber treatment: The subjects breathe air freely in the imitation environment chamber at 1.0bars.
Study: NCT01186666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary intervention using IVUS-VH & FDG PET-MDCT
Description: All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coronary intervention using IVUS-VH & FDG PET-MDCT
Description: All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.
Study: NCT03780049

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: HAIC of FOLFOX
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HAIC of FOLFOX
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H101
Description: Patients receive H101 0.5ml dissolved in 10ml normal saline in each session of HAIC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Patients receive normal saline 10ml in each session of HAIC
Study: NCT02266316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Air warming mask
Description: Mask that warms air at the mouth
Study: NCT06301230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable Laparoscopic Trainer (PLET)
Description: The PLET trainer is light and easy to transport packed in a bag and consists of a foldable plastic box, which can be assembled in less than 30 seconds by means of simple handles. There are three accesses for the surgical instruments (ports) as well as a central recess over which a tablet with an integrated camera can be placed.~Each participant received a previously prepared opaque envelope containing a black or white USB stick from the Principal Investigator with the assignments on it as part of the randomization process. The outcome assessors were blinded to the allocation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portable Laparoscopic Trainer (PLET)
Description: The PLET trainer is light and easy to transport packed in a bag and consists of a foldable plastic box, which can be assembled in less than 30 seconds by means of simple handles. There are three accesses for the surgical instruments (ports) as well as a central recess over which a tablet with an integrated camera can be placed.~Each participant received a previously prepared opaque envelope containing a black or white USB stick from the Principal Investigator with the assignments on it as part of the randomization process. The outcome assessors were blinded to the allocation.
Study: NCT01998230

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: early oral feeding
Description: In the early oral feeding group, the patients are encouraged to intake liquid food on post operative day 1.
Study: NCT04564664

Intervention type: DRUG
Group type: OTHER
Intervention: Oxygen
Description: High-flow nasal cannula oxygen therapy vs. standard oxygen therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Oxygen
Description: High-flow nasal cannula oxygen therapy vs. standard oxygen therapy
Study: NCT02575534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procainamide
Description: the procainamide will be infused at 12mcg/kg up to a max of 1 gram at a rate of 20mg/min which will take up to 1 hour to infuse
Study: NCT04400630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: The experimental group will receive supervised physical exercise treatment by high-intensity interval training (HIT), alternating high and moderate intensities (20 min). The participants will exercise two non-consecutive days per week for 16 weeks under supervision by exercise specialists.
Study: NCT03358277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPH + APZ
Description: MPH was administered with either Ritalin (from 10mg/day to 40mg/day) or Concerta (from 18mg/day to 36mg/day) according to clinical judgement for six weeks. APZ was administered with dose from 2.5mg/day to 5mg/day according to clinical judgement for six weeks.
Study: NCT01671163

Intervention type: PROCEDURE
Intervention: Endoscopic Ultrasound (EUS) for fiducial placement
Description: Endoscopic Ultrasound (EUS) used for the placement of fiducial markers in tissue as outlined by the radiation oncologist
Study: NCT04482517

Intervention type: OTHER
Group type: OTHER
Intervention: Density Gradient Centrifugation
Description: Semen processing is done by double layer density gradient method.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiological ICSI
Description: Sperm selection by PICSI dishes depending on hyaluronan binding of sperm head

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic activated cell sorting
Description: Sperm selection by using Annexin V micro-beads and separation columns

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Testicular sperm
Description: Using testicular sperm retrieved by TESA or TESE
Study: NCT02699658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Study: NCT02730481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.